Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Guangzhou Kingmed Diagnostics (603882.SS)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (Rmb)	Price Target (Rmb)	Rating
2022-03-30	74.17	230.00	Buy
2022-04-19	74.31	100.00	Buy
2022-04-27	75.88	97.00	Buy
2022-04-28	83.47	98.00	Buy
2022-08-18	66.16	97.20	Buy
2022-10-28	74.70	97.80	Buy
2022-12-08	70.15	90.50	Buy
2023-07-17	71.79	89.00	Buy
2023-08-31	59.66	85.60	Buy
2023-10-30	61.04	83.60	Buy
2024-06-21	28.10	32.00	Neutral
2024-09-02	25.66	28.90	Neutral
2025-05-20	30.07	22.80	Sell

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.